Search results
Showing 106 to 120 of 208 results for lymphoma
Awaiting development Reference number: GID-TA11843 Expected publication date: TBC
Awaiting development Reference number: GID-TA11705 Expected publication date: TBC
Awaiting development Reference number: GID-TA11976 Expected publication date: TBC
Lymphoma (non Hodgkin's) - bendamustine (with rituximab) [ID434]
Discontinued Reference number: GID-TAG278
Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]
Discontinued Reference number: GID-TAG321
Past technology appraisal appeals and decisions
Awaiting development Reference number: GID-TA11867 Expected publication date: TBC
Awaiting development Reference number: GID-TA12036 Expected publication date: TBC
Lymphoma (follicular non Hodgkin's - advanced) - bortezomib [ID407]
Discontinued Reference number: GID-TAG425
Mogamulizumab for previously treated T-cell leukaemia-lymphoma [ID1390]
Discontinued Reference number: GID-TA10464
Ibrutinib combination therapy for untreated diffuse large B-cell lymphoma [ID997]
Discontinued Reference number: GID-TA10382
Lymphoma (non Hodgkin's, peripheral T-cell) - pralatrexate [ID368]
Discontinued Reference number: GID-TAG424
T-cell lymphoma (peripheral, relapsed or refractory) - romidepsin [ID504]
Discontinued Reference number: GID-TAG433
Lymphoma (diffuse large B-cell, untreated) – liposomal vincristine [ID1123]
Discontinued Reference number: GID-TA11208
Evidence-based recommendations on erythropoiesis-stimulating agents (epoetin alfa [Eprex], epoetin beta [NeoRecormon], epoetin theta, epoeitin zeta [Retacrit] and darbepoetin alfa [Aranesp]) for treating anaemia in adults with cancer having chemotherapy.